Supplemental table. Age distribution of HCVAb positivity by birth cohort in hospitalized COVID-19 patients

| Age<br>cohorts | COVID-19<br>infected<br>n=332 (%) | COVID-19<br>deceased<br>n=90 (%) | HCV Abs<br>positivity<br>n=10 (%) | HCV Ab positivity in Italy <sup>7</sup> |                 |
|----------------|-----------------------------------|----------------------------------|-----------------------------------|---|-----------------|
|                |                                   |                                  |                                   | North<br>South                          |                 |
| ≤45 yrs        | 24 (7.2)                          | 1/24 (4.1)                       | 0/24                              | 1/325<br>(0.3%)                         | 3/598<br>(0.5%) |
| 46-55          | 31 (9.3)                          | 5/31(16.1)                       | 1/31(3.2%)*                       | 2/180<br>(1.1%)                         | 9/518<br>(1.7%) |
| 56-65          | 64 (19.3)                         | 6/64 (9.3)                       | 4/64 (6.2%)                       | 5/172<br>(2.9%)                         | 5/677<br>(0.7%) |
| 66-75          | 78 (23.5)                         | 24/78 (30.7)                     | 1/78 (1.3%)                       | 4/151<br>(2.6%)                         | 15/639 (2.3%)   |
| 76-85          | 87 (26.2)                         | 34/87(39.0)                      | 2/87 (2.3%)^                      | 4/124<br>(3.2%)                         | 32/374 (8.6%)   |
| >85            | 48 (14.5)                         | 20/48 (41.6)                     | 2/48 (4.1%)§                      | 0/45<br>(0)                             | 6/104<br>(5.8%) |

\*1/2 was HCVAb/antiHIV positive and died; §2 HCVAb non cirrhotic patients died; ^1 HCVAb, HCV-RNA reactive cirrhotic patient died